MBRX (Moleculin Biotech) 3-Year RORE % : -61.81% (As of Mar. 2026)


MBRX Moleculin Biotech Inc MBRX
30 GF Score
Price $2.64
! 1 Warning Sign
View Full Analysis

What is Moleculin Biotech 3-Year RORE %?

Moleculin Biotech MBRX -1.86% 30 3-Year RORE % is -61.81 as of Mar. 2026. GuruFocus rates MBRX with a GF Score™ of 30/100. The stock has 1 warning sign investors should review. Among 1,293 Biotechnology companies, Moleculin Biotech ranks worse than 86.47% on this metric.

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Moleculin Biotech's 3-Year RORE % for the quarter that ended in Mar. 2026 was -61.81%.

The industry rank for Moleculin Biotech's 3-Year RORE % or its related term are showing as below:

MBRX's 3-Year RORE % is ranked worse than
86.47% of 1293 companies
in the Biotechnology industry
Industry Median: -11.55 vs MBRX: -61.81

Moleculin Biotech  (NAS:MBRX) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Moleculin Biotech 3-Year RORE % Related Terms


Moleculin Biotech 3-Year RORE % Historical Data

* Premium members only.

The historical data trend for Moleculin Biotech's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Moleculin Biotech 3-Year RORE % Chart

Moleculin Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
3-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -33.87 -20.79 15.93 -23.89 -58.17

Moleculin Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
3-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -31.63 -36.87 -40.35 -58.17 -61.81

MBRX vs JAGX, BCDA, AKTX: 3-Year RORE % Comparison

For the Biotechnology subindustry, Moleculin Biotech's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Moleculin Biotech 3-Year RORE % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Moleculin Biotech's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where Moleculin Biotech's 3-Year RORE % falls into.


MBRX
30GF Score
Moleculin Biotech Inc MBRX
3-Year RORE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Moleculin Biotech 3-Year RORE % Calculation

Moleculin Biotech's 3-Year RORE % for the quarter that ended in Mar. 2026 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( -27.961--324.75 )/( -480.151-0 )
=296.789/-480.151
=-61.81 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.

Frequently Asked Questions Learn more about 3-Year RORE % →
What does a 3-Year RORE % of -61.81 mean?
Moleculin Biotech (MBRX) has a 3-Year RORE % of -61.81 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Moleculin Biotech and its competitors. According to the industry distribution chart, Moleculin Biotech ranks #1118 out of 1293 companies in the Biotechnology industry, placing it in the top 86.5%.
Is Moleculin Biotech's 3-Year RORE % too high?
Moleculin Biotech's current 3-Year RORE % is -61.81. Based on the distribution chart, Moleculin Biotech ranks #1118 out of 1293 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Moleculin Biotech has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Moleculin Biotech's 3-Year RORE % compare to JAGX and BCDA?
According to the Biotechnology industry distribution chart, Moleculin Biotech ranks #1118 out of 1293 companies for 3-Year RORE %. This places Moleculin Biotech in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Biotechnology company?
A good 3-Year RORE % depends on the Biotechnology industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Moleculin Biotech and its competitors. Moleculin Biotech's current 3-Year RORE % is -61.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Moleculin Biotech stock overvalued right now?
Moleculin Biotech (MBRX) has a current 3-Year RORE % of -61.81. The current 3-Year RORE % is -61.81. Moleculin Biotech's overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Moleculin Biotech (MBRX), the current 3-Year RORE % is -61.81 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Moleculin Biotech Business Description

Other Exchanges 0K2H:UK
Address 5300 Memorial Drive, Suite 950, Houston, TX, USA, 77007
Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.
30GF Score

Get the complete analysis for MBRX

3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.64
Price